ConductScience.org, home

Paper40565299

Bispecific Antibodies in Solid Tumors: Advances and Challenges.

Shan KS and 7 others. Int J Mol Sci, 2025. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Bispecific Antibodies in Solid Tumors: Advances and Challenges. Papers, record 40565299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40565299

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
5.43, provisional
iCite
Revised in PubMed
2025-06-28
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shan KSKhine Swehttps://orcid.org/0000-0001-8035-0024
2Musleh Ud Din SSaba
3Dalal SShivanihttps://orcid.org/0000-0001-8290-8546
4Gonzalez TTeresita
5Dalal MMisha
6Ferraro PPablo
7Hussein AAtif
8Vulfovich MMichel

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, BispecificMajor topic
NeoplasmsMajor topic
ImmunotherapyMajor topic
Antineoplastic Agents, ImmunologicalMajor topic
Humans
Animals

References119

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127666558The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors.ACS Nano2016https://conductscience.org/library/papers/27666558PubMed
238906157Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial.Cancer Cell2024https://conductscience.org/library/papers/38906157PubMed
339614368The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.J Hematol Oncol2024https://conductscience.org/library/papers/39614368PubMed
438030788PRAME induces genomic instability in uveal melanoma.Oncogene2024https://conductscience.org/library/papers/38030788PubMed
5277575595T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Cancer Immunol Immunother2017https://conductscience.org/library/papers/27757559PubMed
635439029Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.J Clin Oncol2022https://conductscience.org/library/papers/35439029PubMed
734315767Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.Mol Cancer Ther2021https://conductscience.org/library/papers/34315767PubMed
838252906Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.Blood2024https://conductscience.org/library/papers/38252906PubMed
932641320Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.J Immunother Cancer2020https://conductscience.org/library/papers/32641320PubMed
1034922633Recent advances and challenges of bispecific antibodies in solid tumors.Exp Hematol Oncol2021https://conductscience.org/library/papers/34922633PubMed
1136071036Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.Nat Commun2022https://conductscience.org/library/papers/36071036PubMed
1236793213An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.Mol Ther2023https://conductscience.org/library/papers/36793213PubMed
133798106Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987https://conductscience.org/library/papers/3798106PubMed
1439864547Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.J Thorac Oncol2025https://conductscience.org/library/papers/39864547PubMed
1535653122SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study.Clin Cancer Res2022https://conductscience.org/library/papers/35653122PubMed
1637286303Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.J Immunother Cancer2023https://conductscience.org/library/papers/37286303PubMed
1738339430Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?Cancers (Basel)2024https://conductscience.org/library/papers/38339430PubMed
1836343381The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.Mol Cancer Ther2023https://conductscience.org/library/papers/36343381PubMed
1932934330Exploring the NK cell platform for cancer immunotherapy.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/32934330PubMed
2037263673Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.J Immunother Cancer2023https://conductscience.org/library/papers/37263673PubMed

See all 119 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42980888Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42980888PubMed
42881857
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
J Clin Med2026https://conductscience.org/library/papers/42881857PubMed
42463770Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Oncogene2026https://conductscience.org/library/papers/42463770PubMed
42358825A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncol Res2026https://conductscience.org/library/papers/42358825PubMed
42344894Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis.Front Immunol2026https://conductscience.org/library/papers/42344894PubMed
42301527B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression.Mol Biomed2026https://conductscience.org/library/papers/42301527PubMed
42292353Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis.Front Immunol2026https://conductscience.org/library/papers/42292353PubMed
42290048[Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC].Zhongguo Fei Ai Za Zhi2026https://conductscience.org/library/papers/42290048PubMed
42194027Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions.Biomolecules2026https://conductscience.org/library/papers/42194027PubMed
42074315Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.Int J Mol Sci2026https://conductscience.org/library/papers/42074315PubMed
41562776Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives.Antibodies (Basel)2025https://conductscience.org/library/papers/41562776PubMed
41465586Glioblastoma-A Contemporary Overview of Epidemiology, Classification, Pathogenesis, Diagnosis, and Treatment: A Review Article.Int J Mol Sci2025https://conductscience.org/library/papers/41465586PubMed
41355740Functional NK engagers from OmniClic, a common light-chain platform producing fully human-sequence antibodies in a chicken host species.MAbs2025https://conductscience.org/library/papers/41355740PubMed
41262250Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives.Front Immunol2025https://conductscience.org/library/papers/41262250PubMed
41217689Regulatory dynamics of Th17 lymphocytes in oral squamous cell carcinoma: immune modulation and emerging immunotherapies.Immunol Res2025https://conductscience.org/library/papers/41217689PubMed
41214696Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment.Cancer Cell Int2025https://conductscience.org/library/papers/41214696PubMed
41211166Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/41211166PubMed
41179296CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge.Oncol Res2025https://conductscience.org/library/papers/41179296PubMed
41136631
Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.
Cancer Immunol Immunother2025https://conductscience.org/library/papers/41136631PubMed
40992760Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment.Cancer Control2025https://conductscience.org/library/papers/40992760PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40565299

GET https://conductscience.org/api/papers/v1/40565299/references?page=2